Higuet N, Brohée D
Laboratoire de Médecine Expérimentale (Université Libre de Bruxelles), C.H.U. André Vésale, Montigny-le-Tilleul, Belgium.
Int J Immunopharmacol. 1992 Aug;14(6):1107-11. doi: 10.1016/0192-0561(92)90156-f.
Dipyridamole inhibits, by 50% at 10(-6) M and 100% at 10(-5) M, the incorporation of tritiated thymidine by lymphocytes stimulated with 1 microgram/ml phytohaemagglutinin A for 72 h. At the latter concentration, a clinically relevant one, dipyridamole fails to inhibit lymphocyte proliferation and expression of the cell surface stimulation markers, CD25 and HLA-DR, or differential regulation of the CD45 -RA and -RO isoforms, as determined by single laser two-colour flow-cytometry. No significant immunodepressant effect of dipyridamole can be demonstrated in vitro.
双嘧达莫在浓度为10⁻⁶M时可抑制50%，在浓度为10⁻⁵M时可完全抑制经1微克/毫升植物血凝素A刺激72小时的淋巴细胞对氚标记胸腺嘧啶核苷的掺入。在后者这个临床相关浓度下，通过单激光双色流式细胞术测定，双嘧达莫未能抑制淋巴细胞增殖、细胞表面刺激标志物CD25和HLA-DR的表达，也未能抑制CD45-RA和-RO同种型的差异调节。在体外未显示双嘧达莫有显著的免疫抑制作用。
